Analysis
A wave of new S-1 and S-1/A filings hit the SEC this week, spanning cybersecurity (Cycurion, Cyber Enviro-Tech), biotech and medical devices (Scribe Therapeutics, Catheter Precision), semiconductors (Peraso) and several fresh SPAC vehicles (Gold Mountain Acquisition Corp, Laris Growth Acquisition Corp, B&R Technology Merger Corp) -- a reminder that a much broader IPO pipeline is building beneath the mega-cap headlines dominating 2026 coverage.
Individually, none of these filings carry the scale of Agility Robotics' $2.5 billion SPAC debut or SK Hynix's reported multibillion-dollar Nasdaq ADR listing. Collectively, though, they signal something notable: companies well outside the mega-cap tier are choosing to file for public listings now, suggesting the IPO window is open widely enough to support activity across the full size spectrum, not just the handful of headline-grabbing names.
The SPAC filings specifically -- Gold Mountain, Laris Growth, B&R Technology -- are worth watching alongside Agility Robotics' own SPAC route to its public debut. SPAC structures fell heavily out of favor following the 2021-2022 boom-and-bust cycle, when many SPAC mergers underperformed badly post-close; a renewed wave of new SPAC vehicle filings in 2026, in categories including hardware and technology, suggests either that the structure is finding a genuine second life for the right kind of company, or that sponsors are betting on a receptive market before conditions change.
“Individually, none of these filings carry the scale of Agility Robotics' $2.5 billion SPAC debut or SK Hynix's reported multibillion-dollar Nasdaq ADR listing.”
Scribe Therapeutics' filing is a useful biotech comparison point: it joins Celea Therapeutics' recent $180 million Phase 3-focused raise and Beeline Medicine's autoimmune financing as part of a broader wave of gene-editing and biotech companies testing public-market appetite in 2026, following a multi-year stretch where biotech IPOs had been comparatively scarce.
Compared to 2021's SPAC-heavy IPO boom, which was dominated by consumer and EV-adjacent companies with limited revenue, this cohort of filings looks more sector-diverse and, in categories like cybersecurity and semiconductors, tied to more clearly defined enterprise demand -- though the mix still includes plenty of early-stage or pre-revenue companies typical of any active IPO window.
For public-markets investors and bankers, this filing wave is a useful leading indicator: a genuinely broad IPO pipeline, spanning multiple sectors and structures, tends to signal sustained market receptiveness rather than a narrow, one-off mega-deal moment -- useful context for reading how durable 2026's broader IPO reopening actually is.
The bear case: a high volume of smaller S-1 filings doesn't guarantee successful pricing or aftermarket performance, and the SPAC structure's return carries real historical risk given the poor track record of the 2021-2022 cohort; several of these filers may withdraw or price poorly if broader market sentiment shifts.
What to watch: which of these filings actually price and go effective versus withdraw, how the new SPAC vehicles perform if they complete mergers, and whether this broader filing pipeline continues to build through the second half of 2026 alongside the mega-cap deals getting most of the attention.
